Summary Panel Discussion: Evaluating the Critical Quality Attributes for ADCs as Complex Large & Small Molecule Therapeutics
Reuniting the day’s presenters, don’t miss the final speaker panel discussion to ask any unanswered questions from the scientific presentations. With your fellow process, analytical, and CMC experts, break down the challenges and learnings across impurity qualification, charge variance characterization and comparability studies to best approach ADC regulatory submissions and understand the unique considerations in ADC CQAs from a small and large molecule perspective.